Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)
- PDF / 2,000,813 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 96 Downloads / 176 Views
ORIGINAL ARTICLE – CLINICAL ONCOLOGY
Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive‑stage small cell lung cancer (SCLC) Xiaoting Ma1 · Shan Wang1 · Yujian Zhang1 · Huamin Wei2 · Jing Yu1 Received: 14 May 2020 / Accepted: 18 August 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Background To evaluate the efficacy and safety of an immune checkpoint inhibitor (ICI) combined with chemotherapy in patients with advanced SCLC. Methods We searched published randomized-controlled trials (RCTs) to compare the effect of ICIs combined with chemotherapy and chemotherapy alone on SCLC. The extracted data included the number of people who achieved an objective response rate (ORR), the disease control rate (DCR), the hazard ratio (HR) of progression-free survival (PFS), and the overall survival (OS) with 95% confidence intervals (95% CI). Results Six RCTs involving 2477 patients were included. Compared with chemotherapy alone, patients receiving an ICI combined with chemotherapy had a significantly longer PFS (HR, 0.91; 95% CI 0.88–0.95, p
Data Loading...
